CN109645476A - 一种虫草钙压片组合物及其制备方法 - Google Patents
一种虫草钙压片组合物及其制备方法 Download PDFInfo
- Publication number
- CN109645476A CN109645476A CN201910113725.4A CN201910113725A CN109645476A CN 109645476 A CN109645476 A CN 109645476A CN 201910113725 A CN201910113725 A CN 201910113725A CN 109645476 A CN109645476 A CN 109645476A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- calcium
- cordyceps sinensis
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 49
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 48
- 239000011575 calcium Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229910001868 water Inorganic materials 0.000 claims abstract description 26
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 24
- 239000003765 sweetening agent Substances 0.000 claims abstract description 24
- 239000002562 thickening agent Substances 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 229940088594 vitamin Drugs 0.000 claims abstract description 22
- 229930003231 vitamin Natural products 0.000 claims abstract description 22
- 235000013343 vitamin Nutrition 0.000 claims abstract description 22
- 239000004014 plasticizer Substances 0.000 claims abstract description 21
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 46
- 239000000843 powder Substances 0.000 claims description 45
- 239000002994 raw material Substances 0.000 claims description 42
- 229940069765 bean extract Drugs 0.000 claims description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 22
- 229960000304 folic acid Drugs 0.000 claims description 22
- 235000019152 folic acid Nutrition 0.000 claims description 22
- 239000011724 folic acid Substances 0.000 claims description 22
- 241000205585 Aquilegia canadensis Species 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 19
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 19
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 18
- 241000169546 Lycium ruthenicum Species 0.000 claims description 17
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 17
- 235000019155 vitamin A Nutrition 0.000 claims description 17
- 239000011719 vitamin A Substances 0.000 claims description 17
- 229940045997 vitamin a Drugs 0.000 claims description 17
- 241000208340 Araliaceae Species 0.000 claims description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 14
- 241000190633 Cordyceps Species 0.000 claims description 12
- 240000007049 Juglans regia Species 0.000 claims description 12
- 235000009496 Juglans regia Nutrition 0.000 claims description 12
- 241000180649 Panax notoginseng Species 0.000 claims description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 12
- 241000191896 Rana sylvatica Species 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 12
- 239000005018 casein Substances 0.000 claims description 12
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 12
- 235000021240 caseins Nutrition 0.000 claims description 12
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 12
- 235000021323 fish oil Nutrition 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- 210000003101 oviduct Anatomy 0.000 claims description 12
- 235000019165 vitamin E Nutrition 0.000 claims description 12
- 239000011709 vitamin E Substances 0.000 claims description 12
- 229940046009 vitamin E Drugs 0.000 claims description 12
- 235000020234 walnut Nutrition 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 239000000419 plant extract Substances 0.000 claims description 11
- 235000019163 vitamin B12 Nutrition 0.000 claims description 11
- 239000011715 vitamin B12 Substances 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- 102000004407 Lactalbumin Human genes 0.000 claims description 10
- 108090000942 Lactalbumin Proteins 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 10
- 229960003495 thiamine Drugs 0.000 claims description 10
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229930003451 Vitamin B1 Natural products 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 9
- 235000010374 vitamin B1 Nutrition 0.000 claims description 9
- 239000011691 vitamin B1 Substances 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 235000007215 black sesame Nutrition 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 8
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 8
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 239000011781 sodium selenite Substances 0.000 claims description 7
- 229960001471 sodium selenite Drugs 0.000 claims description 7
- 235000015921 sodium selenite Nutrition 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 229930003537 Vitamin B3 Natural products 0.000 claims description 6
- 244000013123 dwarf bean Species 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019160 vitamin B3 Nutrition 0.000 claims description 6
- 239000011708 vitamin B3 Substances 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 235000020712 soy bean extract Nutrition 0.000 claims description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
- 235000019408 sucralose Nutrition 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 239000011576 zinc lactate Substances 0.000 claims description 5
- 235000000193 zinc lactate Nutrition 0.000 claims description 5
- 229940050168 zinc lactate Drugs 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 229960000359 chromic chloride Drugs 0.000 claims description 4
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 4
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 4
- 239000000626 magnesium lactate Substances 0.000 claims description 4
- 235000015229 magnesium lactate Nutrition 0.000 claims description 4
- 229960004658 magnesium lactate Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- -1 sorbierite Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 3
- 244000126002 Ziziphus vulgaris Species 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 239000012528 membrane Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 30
- 238000001471 micro-filtration Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 239000000919 ceramic Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 238000000605 extraction Methods 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 240000005250 Chrysanthemum indicum Species 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 238000001035 drying Methods 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 210000000988 bone and bone Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000000108 ultra-filtration Methods 0.000 description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 238000001728 nano-filtration Methods 0.000 description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229910052725 zinc Inorganic materials 0.000 description 12
- 239000011701 zinc Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 241001247821 Ziziphus Species 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 11
- 238000010257 thawing Methods 0.000 description 11
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 9
- 244000046052 Phaseolus vulgaris Species 0.000 description 8
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- 206010006956 Calcium deficiency Diseases 0.000 description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229910052804 chromium Inorganic materials 0.000 description 7
- 239000011651 chromium Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 229940091250 magnesium supplement Drugs 0.000 description 7
- 238000000199 molecular distillation Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 241000207961 Sesamum Species 0.000 description 6
- 235000003434 Sesamum indicum Nutrition 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 5
- 206010048259 Zinc deficiency Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- 239000011669 selenium Substances 0.000 description 5
- 229940091258 selenium supplement Drugs 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 235000019158 vitamin B6 Nutrition 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920000049 Carbon (fiber) Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052581 Si3N4 Inorganic materials 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 229940087511 calcium disodium versenate Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000004917 carbon fiber Substances 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000005238 degreasing Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- SIWVEOZUMHYXCS-UHFFFAOYSA-N oxo(oxoyttriooxy)yttrium Chemical compound O=[Y]O[Y]=O SIWVEOZUMHYXCS-UHFFFAOYSA-N 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 102000040350 B family Human genes 0.000 description 3
- 108091072128 B family Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 238000003763 carbonization Methods 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000004332 deodorization Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 229960003581 pyridoxal Drugs 0.000 description 3
- 235000008164 pyridoxal Nutrition 0.000 description 3
- 239000011674 pyridoxal Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- 229910001928 zirconium oxide Inorganic materials 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 229910017083 AlN Inorganic materials 0.000 description 2
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910052582 BN Inorganic materials 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000036119 Frailty Diseases 0.000 description 2
- 206010018275 Gingival atrophy Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 244000017020 Ipomoea batatas Species 0.000 description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 description 2
- 208000019926 Keshan disease Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 206010039921 Selenium deficiency Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 241000893966 Trichophyton verrucosum Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 201000005562 gingival recession Diseases 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000007603 infrared drying Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940029329 intrinsic factor Drugs 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- HYXGAEYDKFCVMU-UHFFFAOYSA-N scandium(III) oxide Inorganic materials O=[Sc]O[Sc]=O HYXGAEYDKFCVMU-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MTPVUVINMAGMJL-UHFFFAOYSA-N trimethyl(1,1,2,2,2-pentafluoroethyl)silane Chemical compound C[Si](C)(C)C(F)(F)C(F)(F)F MTPVUVINMAGMJL-UHFFFAOYSA-N 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-JGVFFNPUSA-N (1r,5s)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-7-one Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2=O IECBDTGWSQNQID-JGVFFNPUSA-N 0.000 description 1
- OVBPIULPVIDEAO-GFCCVEGCSA-N (2r)-2-[[4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-GFCCVEGCSA-N 0.000 description 1
- OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- IECBDTGWSQNQID-UHFFFAOYSA-N Chrysanthenon Natural products CC1=CCC2C(C)(C)C1C2=O IECBDTGWSQNQID-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-SFYZADRCSA-N Chrysanthenone Natural products CC1=CC[C@H]2C(C)(C)[C@@H]1C2=O IECBDTGWSQNQID-SFYZADRCSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- ACBOFPQSBWBAQR-UHFFFAOYSA-N Cosmosiin Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(Oc3c2)c4cccc(O)c4)C(O)C(O)C1O ACBOFPQSBWBAQR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018745 Growing pains Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- HZUKSQHMCTUZJL-UHFFFAOYSA-N P(=O)(O)(O)OCC=1C(=C(C(=NC1)C)O)C=O.P(=O)(O)(O)OC=1C(=NC=C(C1C=O)CO)C Chemical compound P(=O)(O)(O)OCC=1C(=C(C(=NC1)C)O)C=O.P(=O)(O)(O)OC=1C(=NC=C(C1C=O)CO)C HZUKSQHMCTUZJL-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010043183 Teething Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- CGLXTBACLXZPED-UHFFFAOYSA-N [4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-yl] dihydrogen phosphate Chemical compound Cc1ncc(CO)c(CN)c1OP(O)(O)=O CGLXTBACLXZPED-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QBYFCXBVWQQXFH-UHFFFAOYSA-N acaciin Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4OC6OCC(O)C(O)C6O)cc3O2 QBYFCXBVWQQXFH-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- NGPGYVQZGRJHFJ-UHFFFAOYSA-N chembl1604790 Chemical compound OC1=CC(O)=CC=C1N=NC1=CC=C([N+]([O-])=O)C=C1 NGPGYVQZGRJHFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037123 dental health Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 125000003391 methylcobalamin group Chemical group 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 229940030966 pyrrole Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000009288 screen filtration Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ORFSSYGWXNGVFB-UHFFFAOYSA-N sodium 4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazenyl]-3-methoxyphenyl]-2-methoxyphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonic acid Chemical compound COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)OC)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O.[Na+] ORFSSYGWXNGVFB-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000955 splenic vein Anatomy 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种虫草钙压片组合物及其制备方法,所述组合物的原料组份及重量份配比为:主成分80‑150份、增塑剂5‑15份、增稠剂3‑8份、甜味剂1‑5份、纯净水120‑200份、微量元素8‑15份、维生素3‑5份。
Description
技术领域
本发明属于食品技术领域,主要涉及一种虫草钙压片组合物及其制备方法。
背景技术
骨质疏松是以骨量减少、骨微观结构改变为特征,从而导致骨脆性增加,易发生骨折的一种全身性骨病,以疼痛、身高缩短、驼背以及骨折为主要临床表现和体征。随着我国人均寿命的延长,人们生活水平的不断提高,骨质疏松所表现出来的乏力、疼痛以及易骨折等情况越来越受到人们的重视,严重的影响中老年人的生活质量。
中华医学中,骨质疏松属“骨痿”范畴,最先见于《素问.痿论篇》,其认为骨痿的病因有肾气、原行劳倦等原因,其基本病因由于先天禀赋不足、后天调养失宜、久病失治、老年衰变。近年来运用中西医药治疗骨质疏松取得了丰硕的医学成果,但从根本上来说,提高人体免疫力,有效补肾,是治愈骨质疏松的关键,因此利用中药资源和现代实验技术手段,是当前治疗骨质疏松药物发展的趋势。
虫草是传统的滋补强身名贵中药,传统的中医理论认为,虫草入肺肾,既能补肺阴,又能补肾阳,还是治虚症、虚痞、虚痛的良药。研究表明,蛹虫草含有蛋白质、脂类、糖类、维生素及多种微量元素,18种氨基酸齐全,而且含有虫草酸、虫草素、虫草多糖和超氧化物歧化酶等生物活性物质,并且含量十分丰富。研究者将其与野生冬虫夏草的化学成分进行对比研究,其中蛋白质、糖类、脂类、维生素及多种微量元素、18种氨基酸、虫草素、虫草酸、虫草多糖和SOD等化学成分,在含量上基本相同。
黑枸杞在藏医中主要用作中药,民间作滋补肝肾强壮,养血生精以及降压药用,被收载于《四部医典》和《晶珠本草》等藏药经典著作中。经相关研究者测定,黑黑枸杞含有17种氨基酸,13种微量元素,其中钙、镁、铜、锌、铁的含量也高于红色黑枸杞,黑黑枸杞含有红黑枸杞所有的有效成份,但营养比其丰富,其药用、保健价值远远高于普通红黑枸杞,其被誉为“软黄金”。
乳矿物盐以新鲜乳清为原料,经沉淀、浓缩、干燥,去除蛋白质、乳糖等成分而制成的一种富含钙和磷的牛奶矿物质来源,通过膜技术分离浓缩得到的富含钙质的新资源食品原料,可为各种食品和营养补充剂带来近似于牛奶中的矿物质组合。乳矿物盐从牛奶中分离,天然、安全,因为与人体骨骼、牙齿的组成接近,可被人体有效吸收与利用,合理的钙磷比使补钙效果更好。同时,补钙效果不会发生逆转,增加的骨密度即使在停止补充乳矿物盐三年后依然保持,而无机钙停止补充后已增加的骨密度会逐渐消失。
金银花:善于化毒,故治痈疽、肿毒、疮癣。金银花常用于清热解毒,治疗温病发热,热毒血痢,痈疡等症。《本草纲目》载“金银花,善于化毒,故治痈疽、肿毒、疮癣……”。自古以来,金银花常用于清热解毒,治疗温病发热,热毒血痢,痈疡等症。现代药理研究表明,金银花具有抑菌、抗病毒、抗炎、解热、调节免疫等作用。具有清热、解毒、凉风散热的功效,具有广谱抗菌及抗氧化的作用。亦用于风热感冒,支气管炎等病症。研究表明:金银花所含绿原酸(chlorogenic acid,CGA),具有抗菌、抗诱变、抗癌及增强免疫功能的作用。抗癌作用的机理,是促氧化作用抑制致癌物-DNA加合物及氧自由基的形成。抗菌:试验表明金银花对伤寒杆菌、副伤寒杆菌、大肠杆菌、变形杆菌、绿脓杆菌、百日咳杆菌、霍乱弧菌、葡萄球菌、链球菌、肺炎双球菌、脑膜炎球菌等均有抑制作用。
乳酸锌:含有人体中不可缺少的元素锌。锌有着重要的生理功能,①是人体中100多种酶的组成部分。这些酶在组织呼吸和蛋白质、脂肪、糖、核酸等代谢中起重要作用。②锌是DNA聚合酶的必需组成部分。缺锌时蛋白质合成障碍,可导致侏儒症、损伤组织愈合困难、胎儿发育受影响。③锌参加唾液蛋白构成,锌缺乏可导致味觉迟钝,食欲减退。④锌参加维生素A还原酶和视黄醇结合蛋白的合成。⑤促进性器官正常发育保持正常的性功能。缺锌导致性成熟迟缓,性器官发育不全,性功能降低,精子减少,月经不正常。⑥保护皮肤健康。缺锌时皮肤粗糙、干燥、上皮角化和食道类角化;伤口愈合缓慢,易受感染。⑦维护免疫功能。根据锌在DNA合成中的作用,缺锌时导致免疫细胞增殖减少,胸腺活力降低。由于锌在抗氧化生化酶中的作用,缺锌导致细胞表面受体发生变化。⑧其他功能:锌有助于清除体内胆固醇,防治动脉粥样硬化症;锌有助于抑制癌症的发生等。
亚硒酸钠:硒的主要生理功能:①、是谷胱甘肽过氧化物酶的组成成分,清除体内过氧化物,保护细胞和组织免受过氧化物的损害。②、非酶硒化物具有很好的清除体内自由基的功能,可提高肌体的免疫力,抗衰老。③、可维持心血管系统的正常结构和功能,预防心血管病。④、是部分有毒的重金属元素如镉、铅的天然解毒剂。⑤、有效提高肌体免疫力,具有抗化学致癌功能。⑥、预防和治疗克山病和大骨节病。硒可通过四个途径抑制癌细胞的变生与发展:一是降低致癌因子的诱变性;二是直接影响致癌物的代谢;三是通过谷胱甘肽过氧化物酶防止自由基损伤;四是通过干扰肝细胞内的能量代谢,抑制癌细胞。动物实验证明,硒能使老鼠患乳腺癌的发病率从82%降到10%。我国江苏省启东地区是肝癌、肝炎高发区,中国医学科学院肝癌研究所的专家,经过16年用补硒的方法在该地区治疗肝癌和肝炎,结果肿瘤癌前病变发生率下降77%。缺硒会诱发肝坏死,缺硒会诱发心血管疾病。人体缺乏硒是引起克山病的一个重要病因。
磷酸三钙:钙元素在身体的功能和缺乏症。①99%的钙分布在骨骼和牙齿中。20岁之前是骨骼的生长阶段,长个子的时候。人有两个生长高峰期:1岁以前(儿童缺钙将导致发育迟缓,发育不良。诸如出牙晚、学步晚、鸡胸)和12-14岁(身材矮小、生长痛)。20岁以后骨质依然在增加。35-40岁,骨密度达到峰值。40岁以后骨钙逐渐流失(对老年人将加快骨钙的流失,导致身材变短,骨质疏松和骨质增生)。②1%的钙分布在血液、细胞间液及软组织中。保持血钙的浓度对维持人体正常的生命活动有着致关重要的作用。人体有一套机制来维持血钙的浓度。血钙的来源有两个:通过消化道吸收的钙以及骨骼中的钙(骨骼是人体钙的大仓库,当摄入钙不足时,则动用仓库应急)这一切通过甲状旁腺分泌升血钙素和降血钙素来加以调节。③.缺钙会降低软组织的弹性和韧性。皮肤缺弹性显得松垮,衰老;眼睛晶状体缺弹性,易近视、老花;血管缺弹性易硬化。④.降低神经细胞的兴奋性,所以说钙是一种天然的镇静剂。缺钙会导致神经性偏头痛(占女性的10%--20%)、烦躁不安、失眠。对婴儿会引起夜惊、夜啼、盗汗。缺钙还会诱发儿童的多动症。⑤.强化神经系统的传导功能。钙有助于神经递质的产生和释放。⑥.维持肌肉神经的正常兴奋。如血钙增高可抑制肌肉、神经的兴奋性;当血钙低于70mg/L时,神经肌肉的兴奋性升高,出现抽搐。肠激综合症、女孩子痛经,缺钙是一个重要原因。⑦.降低(调节)细胞和毛细血管的通透性。缺钙易导致过敏,水肿等。⑧.促进体内多种酶的活动。缺钙时,腺细胞的分泌作用减弱。钙还是酶的激活剂。⑨.维持酸碱平衡。⑩.参与血液的凝固过程。血的凝固是一个复杂的过程,其中一个步骤是:凝血酶原-具有活性的凝血酶,其中需要有钙来激活。
乳酸镁:镁元素是构成人体内多种酶的重要来源。镁尽管在人体中的含量微乎其微,可缺乏镁元素人们就会精神疲惫、面黄肌瘦、皮肤粗糙,甚至情绪不稳定,面部、四肢肌肉颤抖。如果镁元素缺乏或偏低,则可适当服用具有补镁作用的药物。据研究,无花果、香蕉、杏仁、冬瓜子、玉米、红薯、黄瓜、珍珠粉、蘑菇、柿子、黄豆、紫菜、橘子等,含有丰富的镁元素。
三氯化铬:微量元素铬有随年龄增长而下降的趋势且与糖代谢关系密切。铬是人体必须的微量元素,三价铬的缺乏是糖尿病发病的原因之一。当机体缺铬后,影响了葡萄糖在体内的正常代谢,使人体的葡萄糖耐量下降,胰岛素的活性及敏感性下降。胰岛素是糖代谢的核心物质,是体内唯一降血糖的激素。因此,胰岛素发挥作用,就必须有铬的参加。另外铬元素可协助胰岛素发挥作用,防止动脉硬化,促进蛋白质代谢合成,促进生长发育等。
维生素A:是一种复杂机体必需的营养素,它以不同方式几乎影响机体的一切组织细胞。尽管是一种最早发现的维生素,但有关它的生理功能至今尚末完全揭开。就目前的已知而言,维生素A(包括胡萝卜素)最主要生理功能包括:①维持视觉:维生素A可促进视觉细胞内感光色素的形成。维生素A可调试眼睛适应外界光线的强弱的能力,以降低夜盲症和视力减退的发生,维持正常的视觉反应,有助于对多种眼疾(如眼球干燥与结膜炎等的治疗)。维生素A对视力的作用是被最早发现的、也是被了解最多的功能。②促进生长发育:与视黄醇对基因的调控有关视黄醇也具有相当于类固醇激素的作用,可促进糖蛋白的合成。促进生长、发育,强壮骨骼,维护头发、牙齿和牙床的健康。③维持上皮结构的完整与健全。视黄醇和视黄酸可以调控基因表达,减弱上皮细胞向鳞片状的分化,增加上皮生长因子受体的数量。因此,维生素A可以调节上皮组织细胞的生长,维持上皮组织的正常形态与功能。保持皮肤湿润,防止皮肤黏膜干燥角质化,不易受细菌伤害,有助于对粉刺、脓包、疖疮,皮肤表面溃疡等症的治疗;有助于祛除老年斑;能保持组织或器官表层的健康。缺乏维生素A,会使上皮细胞的功能减退,导致皮肤弹性下降,干燥粗糙,失去光泽。④加强免疫能力:维生素A有助于维持免疫系统功能正常,能加强对传染病特别是呼吸道感染及寄生虫感染的身体抵抗力;有助于对肺气肿、甲状腺机能亢进症的治疗。⑤清除自由基:维生素A也有一定的抗氧化作用,可以中和有害的游离基。另外,研究显示皮肤癌、肺癌、喉癌、膀胱癌和食道癌都跟维生素A的摄取量有关。
维生素B1:又名硫胺素,在人体内转变成硫胺素焦磷酸,参与糖在体内的代谢。因此维生素B1缺乏时,糖在组织内的氧化受到影响。它还有抑制胆碱酯酶活性的作用,缺乏维生素B1时此酶活性过高,乙酰胆碱(神经递质之一)大量破坏使神经传导受到影响,可造成胃肠蠕动缓慢,消化道分泌减少,食欲不振、消化不良等障碍。
维生素B2:又名核黄素,是橙黄色针状晶体,味微苦,水溶液有黄绿色荧光,在碱性或光照条件下极易分解。人体缺少它易患口腔炎、皮炎、微血管增生症等。成年人每天应摄入2~4mg,它大量存在于谷物、蔬菜、牛乳和鱼等食品中。
维生素B3:又名烟酸,它不但是维持消化系统健康的维生素,也是性荷尔蒙合成不可缺少的物质。对生活充满压力的现代人来说,烟酸维系神经系统健康和脑机能正常运作的功效,也绝对不可以忽视。建议日摄取量:成人的建议每日摄取量是13~19mg。孕妇(孕妇产品,孕妇资讯)为20mg;哺乳期妇女则为22mg。
维生素B6:吡哆醇类,具有抑制呕吐、促进发育等功能,缺少它会引起呕吐、抽筋等症状。包括三种物质,即吡哆醇、吡哆醛及吡哆胺。吡哆醇在体内转变成吡哆醛,吡哆醛与吡哆胺可相互转变。酵母、肝、瘦肉及谷物、卷心菜等食物中均含有丰富的维生素B6。维生素B6易溶于水和酒精,稍溶于脂肪溶剂;遇光和碱易被破坏,不耐高温。维生素B6在体内与磷酸结合成为磷酸吡哆醛或磷酸吡哆胺。它们是许多种有关氨基酸代谢酶的辅酶,故对氨基酸代谢十分重要。
维生素B9:又名叶酸。叶酸是由喋啶,对氨基苯甲酸和谷氨酸残基组成的一种水溶性B族维生素,亦称为维生素BC或维生素M;在蔬菜叶、肝脏中含量丰富。叶酸是一种广泛存在于绿色蔬菜中的B族维生素,由于它最早从植物叶子中提取而得,故命名为″叶酸″。叶酸的化学名为″蝶酰谷氨酸″,系由喋啶酸、对氨基苯甲酸与氨酸结合而成。
叶酸对人体的重要营养作用早在1948年即已得到证实,人类(或其他动物)如缺乏叶酸可引起巨红细胞性贫血以及白细胞减少症。此外,研究还发现,叶酸对孕妇尤其重要。如在怀孕头3个月内缺乏叶酸,可导致胎儿神经管发育缺陷,从而增加裂脑儿,无脑儿的发生率。其次,孕妇经常补充叶酸,可防止新生儿体重过轻、早产以及婴儿腭裂(兔唇)等先天性畸形。
维生素B12:又称钴胺素,抗恶性贫血维生素,含有金属元素钴,是维生素中唯一含有金属元素的。抗脂肪肝,促进维生素A在肝中的贮存;促进细胞发育成熟和机体代谢。它与其他B族维生素不同,一般植物中含量极少,而仅由某些细菌及土壤中的细菌生成。肝、瘦肉、鱼、牛奶及鸡蛋是人类获得维生素B12的来源。商品可从制造某些抗生素的副产品或特殊的发酵制得。维生素B12是粉红色结晶,水溶液在弱酸中相当稳定,强酸、强碱下极易分解,日光、氧化剂及还原剂均易破坏维生素B12。它经胃肠道吸收时,须先与胃幽门部分泌的一种糖蛋白(亦称内因子)结合,才能被吸收。因缺乏“内因子”而导致的B12缺乏,治疗应采用注射剂。脱氧腺苷钴胺素是维生素B12在体内主要存在形式。它是一些催化相邻两碳原子上氢原子、烷基、羰基或氨基相互交换的酶的辅酶。体内另一种辅酶形式为甲基钴胺素,它参与甲基的转运,和叶酸的作用常互相关联,它可以增加叶酸的利用率来影响核酸与蛋白质生物合成,从而促进红细胞的发育和成熟。缺乏维生素B12时会发生恶性贫血,人体对B12的需要量极少,人体每天约需12μg(1/1000mg),人在一般情况下不会缺少。
维生素E:能抵抗自由基的侵害,预防癌症及心肌梗死。维生素E是强抗氧化剂,维生素E供应不足会引起各种智能障碍或情绪障碍。小麦胚芽、棉籽油、大豆油、芝麻油、玉米油、豌豆、红薯、禽蛋、黄油等含维生素E较丰富。副作用:每天摄入200毫克的维生素E就会出现恶心,肌肉萎缩,头痛和乏力等症状。每天摄入的维生素E超过300毫克会导致高血压,伤口愈合延缓,甲状腺功能受到限制。
菊花:性味甘苦,凉,味苦,平;归经:入肺、肝经。黄、白两菊,都有疏散风热、平肝明目、清热解毒的功效。白菊花味甘、清热力稍弱,长于平肝明目;黄菊花味苦,泄热力较强,常用于疏散风热;野菊花味甚苦,清热解毒的力量很强。野菊的茎、叶,功用与花相似,无论内服与外敷,都有功效。
化学成分:花和茎含挥发油,并有腺嘌呤、胆碱、水苏碱等。花又含菊甙、氨基酸、黄酮类及微量、维生素B1。挥发油主要含龙脑、樟脑、菊油环酮等。黄酮类有木犀草素-7-葡萄糖甙、大波斯菊甙、刺槐甙。尚含丁二酸二甲基酰肼。药理作用:1、抗病原体作用。菊花在体外对革兰氏阳性细菌(金黄色葡萄球菌及β-溶血性链球菌)、人型结核杆菌有某些抑制作用。其水浸剂对某些常见皮肤致病性真菌亦有些抑制作用。高浓度在体外还有抗病毒(PB8株)及抗螺旋体作用。2、增强毛细血管抵抗力,能抑制毛细血管的通透性而有抗炎作用。其提取物10毫克相当芦丁2.5毫克之效力。
三氯蔗糖:是一种理想的半天然甜味剂,到目前为止尚未发现有什么不足之处!与其它甜味剂相比,它同时具备多项无可比拟的优越性质:①甜度高,是蔗糖的600-650倍;②口味纯正,没有任何异味或苦涩味,甜味特征曲线几乎与蔗糖重叠,这是其它任何甜味剂无法比拟的;③.绝对的安全性,没有任何安全毒理方面的疑问;④能量值为0,不会引起肥胖,可供糖尿病人,心脑血管疾病患者及老年人使用;⑤不会引起血糖波动,可供糖尿病人食用;⑥不会引起龋齿,对牙齿健康有利;⑦具有很好的溶解性和稳定性,从酸性到中性都能使食品的甜味,对酸味和咸味有淡化效果;对涩味、苦味、酒味、等不快的味道有掩盖效果;对辣味、奶味有增效作用,应用范围十分广泛。
维生素C:VC对人体的作用近代研究表明:对人体健康至关重要。①、胶原蛋白的合成需要维生素C参加,所以VC缺乏,胶原蛋白不能正常合成,导致细胞连接障碍。人体由细胞组成,细胞靠细胞间质把它们联系起来,细胞间质的关键成分是胶原蛋白。胶原蛋白占身体蛋白质的1/3,生成结缔组织,构成身体骨架。如骨骼、血管、韧带等,决定了皮肤的弹性,保护大脑,并且有助于人体创伤的愈合。②、坏血病。血管壁的强度和VC有很大关系。微血管是所有血管中最细小的,管壁可能只有一个细胞的厚度,其强度、弹性是由负责连接细胞具有胶泥作用的胶原蛋白所决定。当体内VC不足,微血管容易破裂,血液流到邻近组织。这种情况在皮肤表面发生,则产生淤血、紫癍;在体内发生则引起疼痛和关节涨痛。严重情况在胃、肠道、鼻、肾脏及骨膜下面均可有出血现象,乃至死亡。③、牙龈萎缩、出血。健康的牙床紧紧包住每一颗牙齿。牙龈是软组织,当缺乏蛋白质、钙、VC时易产生牙龈萎缩、出血。④、预防动脉硬化。可促进胆固醇的排泄,防止胆固醇在动脉内壁沉积,甚至可以使沉积的粥样斑块溶解。⑤、是一种水溶性的强有力的抗氧化剂。可以保护其它抗氧化剂,如维生素A、维生素E、不饱和脂肪酸,防止自由基对人体的伤害。⑥、治疗贫血。使难以吸收利用的三价铁还原成二价铁,促进畅道对铁的吸收,提高肝脏对铁的利用率,有助于治疗缺铁性贫血。⑦、防癌。丰富的胶原蛋白有助于防止癌细胞的扩散;VC的抗氧化作用可以抵御自由基对细胞的伤害防止细胞的变异;阻断亚硝酸盐和仲胺形成强致癌物亚硝胺。曾有人对因癌症死亡病人解剖发现病人体内的VC含量几乎为零。⑧、保护细胞、解毒,保护肝脏。在人的生命活动中,保证细胞的完整性和代谢的正常进行至关重要。为此,谷胱甘肽和酶起着重要作用。谷胱甘肽是由谷氨酸、胱氨酸和甘氨酸组成的短肽,在体内有氧化还原作用。它有两种存在形式,即氧化型和还原型,还原型对保证细胞膜的完整性起重要作用。VC是一种强抗氧化剂,其本身被氧化,而使氧化型谷胱甘肽还原为还原型谷胱甘肽,从而发挥抗氧化作用。
发明内容
为克服现有技术中存在的上述问题,本发明人经过深入研究和大量试验,提供了如下技术方案。
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分80-150份、增塑剂5-15份、增稠剂3-8份、甜味剂1-5份、纯净水120-200份、微量元素8-15份、维生素3-5份。
优选,所述主成分的原料组份及重量份配比为:金银花1-3份、甘草5-8份、红枣15-20份、虫草提取物15-30份、豆类提取物25-40份、三七1-3份、菊花5-9份、灵芝孢子粉1-5份、人参1-3份、黑枸杞10-15份、芝麻粉9-15份、核桃粉5-10份、酪蛋白0.1-0.5份、α-乳白蛋白2-4份、雪蛤3-7份、鱼油5-10份。
优选,所述增稠剂选自所述增稠剂是淀粉、纤维素、海藻酸钠、卡拉胶、琼脂、结冷胶、普鲁兰多糖、刺槐豆胶、瓜尔豆胶、黄原胶中的一种、两种或两种以上任意比例的混合物;
优选,所述增塑剂是甘油、丙二醇、山梨醇、聚乙二醇中的一种、两种或两种以上任意比例的混合物;
优选,所述甜味剂为木糖醇、三氯蔗糖、低聚木糖或低聚果糖中的一种;
优选,所述微量元素为亚硒酸钠、乳酸镁、磷酸三钙、乳酸锌或三氯化铬中的一种、两种或两种以上的混合物;
优选,所述维生素为维生素A、维生素B1、维生素B2、维生素B3、维生素B12、维生素C、维生素E、叶酸、维生素D、烟酰胺、泛酸中的一种或几种;
优选,所述豆类提取物为黄豆提取物或青豆提取物或黑豆提取物中的一种或几种提取物的混合物。
优选,所述组合物的原料组份及重量份配比为:
主成分80份、增塑剂5份、增稠剂3份、甜味剂1份、纯净水120份、微量元素8份、维生素3份。
优选,所述组合物的原料组份及重量份配比为:
主成分150份、增塑剂15份、增稠剂8份、甜味剂5份、纯净水200份、微量元素15份、维生素5份。
优选,所述主成分的原料组份及重量份配比为:金银花1份、甘草5份、红枣15份、虫草提取物15份、豆类提取物25份、三七1份、菊花5份、灵芝孢子粉1份、人参1份、黑枸杞10份、芝麻粉9份、核桃粉5份、酪蛋白0.1份、α-乳白蛋白2份、雪蛤3份、鱼油5份。
优选,所述主成分的原料组份及重量份配比为:金银花3份、甘草8份、红枣20份、虫草提取物30份、豆类提取物40份、三七3份、菊花9份、灵芝孢子粉5份、人参3份、黑枸杞15份、芝麻粉15份、核桃粉10份、酪蛋白0.5份、α-乳白蛋白4份、雪蛤7份、鱼油10份。
一种所述虫草钙压片组合物的制备方法,其特征在于,包括如下步骤:
步骤一、原料准备;
步骤二、称量、配料;
步骤三、植物提取物的制备;
步骤四、干燥;
步骤五、混合;
步骤六、灭菌、包装。
所述步骤一、原料准备;
其中,所述原料准备包括:
(一)原料预处理
步骤(1)将金银花、甘草、红枣、菊花、人参、黑枸杞、芝麻粉等原料进行清洗,去除杂质。
步骤(2)将步骤(1)中经过清洗的原料,放在-10到-5℃的冰箱中恒温2-3h,然后取出放在真空冷冻干燥机内,先以3℃/min的降温速度冷冻至-20~-30℃,保持2-4h,然后将冷冻原料放在室温、通风的条件下解冻摊晾至原料表面的冰晶融化、水分挥发,解冻摊晾过程中每隔10分钟翻动一次冷冻原料,解冻摊晾10-11h,即得到解冻原料;
步骤(3)初烘,将步骤(2)中得到的解冻原料均匀的添加至烘干机中,温度为50-55℃的条件下初烘至含水量为10-15%的程度,初烘15-20min,即得到初烘原料,再将初烘原料摊晾1-2h,即得到待复烘原料;
步骤(4)复烘,将步骤(3)中得到的待复烘原料均匀的添加至烘干机中,温度为55-60℃的条件下复烘至待复烘原料含水量为5-8%,复烘15-20min,即得到成品待用原料,所述烘干机的型号为7CHB-5,产量≥30kg/h。
(二)其它组份原料的预处理
灵芝孢子粉的加工工艺为:取灵芝菌盖在9厘米以上,菌柄2厘米以内,干燥、无霉变的灵芝超微粉碎加工。所述超微粉碎加工工艺为,将灵芝密封置于-15到-10℃的冰箱中恒温1-2h,然后取出,置于真空冷冻干燥机内,先以5-10℃/min的降温速度冷冻至-40~-50℃,保持2-4h,然后再放置在库温为-32~-36℃的冷冻库中恒温冷冻3h,在超微破壁粉碎机粉碎至200目以上。
所述步骤二、称量、配料;
将步骤一中得到的预处理后的原料,按照相应的配比进行称量;
步骤三、植物提取物的制备;
所述步骤三的植物提取物的制备,具体包括:
(一)虫草提取物的制备
步骤(1)将虫草在蓝光灭菌机里进行灭菌,灭菌时间1-2min,然后进行干燥,干燥温度50-60℃,干燥时间5-8h,干燥时附加远红外照射,远红外辐射强度0.3-0.4W/cm2;干燥后储藏在冷柜中,储藏温度为-5℃~-10℃;
步骤(2)将冷冻的虫草粉碎至200目,得到虫草粉;
步骤(3)将虫草粉进行造粒,造粒后的颗粒平均粒径为1.0-3.0mm;
步骤(4)将步骤(3)重的虫草颗粒,置于萃取釜中;
步骤(5)将经过预热的去离子水以小于或等于50ml/min的流速注入到萃取釜中;
步骤(6)萃取;
步骤(7)离心:将萃取液在2000-3000r/min条件下,离心处理20-30min,取上清液;
步骤(8)过滤:离心后得到的上清液过微滤陶瓷薄膜,得到滤液,沉淀后取上清精油,得到虫草精油粗品;
步骤(9)虫草精油粗品倒入分子蒸馏仪的物料瓶中并关闭分子蒸馏系统与外界联通的所有阀门,打开冷凝水,将液氮加入到冷阱中,启动真空泵进行脱气,至液面无气泡逸出;
步骤(10)设定分子蒸馏蒸发面温度为为30-50℃、真空度为200-700Pa,待温度与真空度达到设定值时打开进料阀,调节进料流速为1-3mL、转速为200-400r/min脱气后进行粗制精油的分子蒸馏,收集重组分纯化浓缩精油的馏余物,得到虫草提取物,经检测,其中虫草酸含量大于10%,不饱和脂肪酸含量大于90%。
通过本申请所述提取物植物制备方法所取得的虫草提取物,有效成分含量高,损失小,最大程度的保留了其有效成分。
所述微滤陶瓷薄膜过滤中,所述陶瓷薄膜为本申请针对所述虫草植物特性,为最大限度提高提取虫草有效成分的提取率,保证其有效成分的活性而专门设计的。申请人经过大量的研究发现,在现有技术中,研究人员往往忽略对制备提取物过滤步骤的忽略,从而导致提取的效率不高,有效成分的活性低,营养成分损失。通过大量的研究,针对现有技术中的不足,本申请中采用氧化锆基陶瓷薄膜,截留分子量为1500MW,微滤温度为20-25℃;所述薄膜的厚度为10-15微米;所述薄膜的原料组份及重量配比为:氮化硅8-10份、氧化钇稳定的氧化锆5-8份、碳化钛1-3份、碳纤维5-8份、氧化锌1-5份、氮化铝5-8份、立方氮化硼3-4份;
通过本步骤所使用的陶瓷薄膜过滤,对提取物产品无污染,能有效过滤杂质,为提高提取物的纯度,打下了坚实的基础。
在步骤(6)的萃取步骤中,使用超声强化亚临界水进行萃取,包括控制系统部分、操作系统部分和超声强化部分,控制系统部分与操作系统部分之间采用电信号的方式连接。所述亚临界水萃取法,在1-5Mpa、100-150℃条件下,对反应釜中的物质进行60-90min的萃取,然后分离反应釜中的物质。
(二)豆类提取物的制备
步骤a、将豆类洗净,晾干,破碎至0.1cm-0.5cm,豆类料与水的重量比为1:(1.5-2)放入蒸煮罐中进行高温高压提取,得到豆汁和豆渣混合物;将混合物过滤,所述过滤分为粗滤和微滤,所述粗滤使用纱布,所述微滤使用微滤陶瓷薄膜A;所述微滤陶瓷薄膜A为氧化铝基陶瓷薄膜,截留分子量为2000MW,微滤温度为20-25℃;所述微滤陶瓷薄膜A的厚度为15-20微米;所述微滤陶瓷薄膜A的原料组份及重量配比为:氧化铝3-5份、氧化镁1-2份、氧化钇稳定的氧化锆6-9份、Sc2O3 1-3份、碳纤维5-8份、氧化钙1-3份、BeO 5-8份、氮化硅1-2份、碳化硅5-10份。
然后将粗滤与微滤取得的滤渣进行混合,对滤渣混合物进行蒸煮提取:滤渣在蒸煮罐中的提取温度为125-130℃,提取时间为120-180min;将提取后的滤渣汁经过100目的过滤网过滤后,取得的液体与粗滤和微滤取得的滤液进行混合,再进行下一步滤液提纯处理。
步骤b、将步骤一中得到的滤液进行提纯处理,依次包括如下步骤,管式离心分离、超滤膜过滤、脱色脱味、纳滤膜浓缩、离心喷雾干燥;
其中,管式离心分离:将经过过滤后的滤液进行高速离心分离,离心机转速为10000-12000r/min,离心后的脱脂滤液进入超滤膜过滤工序;
其中,超滤膜过滤:将得到的脱脂滤液用截留分子量为1000-2000道尔顿的超滤膜过滤去除清液中的大分子物质,所述超滤膜的膜压为1-1.5MPa,超滤温度为25-30℃;然后进入脱色脱味工序;
其中,脱色脱味:向经过超滤膜过滤后得到的清液中加入活性碳进行脱色脱味,活性碳的加入量为超滤膜过滤后滤液重量的5%-10%,将加入活性碳后的清液升温至85-95℃,并保温10min-30min,然后降温至60℃-70℃,静置30min-60min后经过孔径为0.2-0.5μm的多层膜过滤器进行脱碳处理;然后进入纳滤膜浓缩工序
其中,纳滤膜浓缩:将脱碳处理的清液用孔径分为200-300道尔顿的纳滤膜去除大部分水分和无机盐,将清液浓缩至固形物含量为35-40%,所述纳滤膜的膜压为0.2MPa-0.5MPa,纳滤温度为25℃-40℃;然后进入离心喷雾干燥工序;
其中,离心喷雾干燥:将经过浓缩的滤液液经离心喷雾干燥塔干燥,干燥过程中的进口温度为180℃-190℃,出口温度为75℃-85℃,即得到豆类提取物。
步骤四、干燥;
所述干燥为热风-红外干燥,热风温度45-55℃,远红外辐射强度0.5-1W/cm2。
步骤五、混合;
将步骤三中制备的植物提取物,与步骤二中准备好的配料,按照原料配比组分进行搅拌,混合;
(1)制粒:将各种原料混合好后放入制粒机,筛底选20目筛;
(2)干燥:制粒结束后,迅速干燥,避免结块,干燥温度40-50℃,干燥后的组合物水分为7-8%;
(3)整粒:将干燥好的组合物颗粒过10目筛,使颗粒粒度分布均匀,流动性更好;
步骤六、灭菌、包装。
高温100±2℃灭菌14±2分钟,检验合格后,复合袋分装后包装。
组合物理化指标符合表1的规定。
表1理化指标
项目 | 要求 | 内控指标 |
可溶性固形物(20℃折光计法)% | ≥3.8 | ≥4.0 |
mg/L | ≤20 | 10-11 |
pH值 | 5.0~6.8 | 5.0~6.8 |
总砷(As),mg/L | ≤0.2 | ≤0.2 |
铅(Pb),mg/L | ≤0.2 | ≤0.2 |
锡(Sn),mg/L | ≤200 | ≤200 |
铜(Cu)/(mg/L) | ≤5 | ≤5 |
在本申请中,正是这些具体的步骤引入,为得到具有如本发明所述特点的组合物奠定了基础。
因此,正是由于上述具体工艺参数的设定,相互协同作用,解决了本发明的技术问题并实现了现有技术无法达到的有益效果。
菊花:清热解毒、清肿。平肝明目,利血气,延年;
金银花:清热解毒、通经活络、广谱抗菌、抗病毒。
用甘草和木糖醇提升甜味,起到中和草药苦味的作用。
甘草:补脾益气、滋咳润肺、缓急解毒、调和百药。
加入少量维生素补充人体所需的元量,提升了组合物的功能。含有维生素C,能溶于水的钾、钠、铁、氟等元素,对调节人体血液的PH平衡,保持人体健康很有益处。同时,维生素有消除体内尼古丁,提高细胞抵抗力,同时也起到抗氧化,保鲜的作用。
附图说明
图1:本申请陶瓷薄膜A的SEM图;
图2:是根据本发明实施例2方法获得的虫草提取物的红外光谱图。
有益效果
1、本发明产品中的有效活性成分更容易被人体所吸收,更加丰富组合物的保健功能;
2、本发明添加了相应的植物提取物具有护肝、养胃、宁心安神、明目、降血压、降血脂、降血糖,提高人体免疫力,延缓衰老、保健美容等功效。
3、本发明制备组合物中,氨基酸含量达到4-5%;人体所需不饱和脂肪酸的总体含量能够达到45%以上;
4、通过本申请中所述提取物的制备工艺制备的植物提取,相对于现有技术中使用的方法制备的提取物,有效成分含量提高10-15%,活性达到或者优于现有技术中的工艺。
具体实施方式
实施例1
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分80份、增塑剂5份、增稠剂3份、甜味剂1份、纯净水120份、微量元素8份、维生素3份。
所述主成分的原料组份及重量份配比为:金银花1份、甘草5份、红枣15份、虫草提取物15份、豆类提取物25份、三七1份、菊花5份、灵芝孢子粉1份、人参1份、黑枸杞10份、芝麻粉9份、核桃粉5份、酪蛋白0.1份、α-乳白蛋白2份、雪蛤3份、鱼油5份。
所述增稠剂选自所述增稠剂是淀粉和纤维素的混合物;
所述增塑剂是甘油;
所述甜味剂为木糖醇;
所述微量元素为亚硒酸钠、乳酸镁、磷酸三钙的混合物;
所述维生素为维生素A、维生素B1、维生素B2、维生素B12、维生素C、维生素E、叶酸、维生素D的混合物;
所述豆类提取物为黄豆提取物。
实施例2
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分150份、增塑剂15份、增稠剂8份、甜味剂5份、纯净水200份、微量元素15份、维生素5份。
所述主成分的原料组份及重量份配比为:金银花3份、甘草8份、红枣20份、虫草提取物30份、豆类提取物40份、三七3份、菊花9份、灵芝孢子粉5份、人参3份、黑枸杞15份、芝麻粉15份、核桃粉10份、酪蛋白0.5份、α-乳白蛋白4份、雪蛤7份、鱼油10份。
所述增稠剂为海藻酸钠;
所述增塑剂是山梨醇;
所述甜味剂为低聚木糖;
所述微量元素为亚硒酸钠、磷酸三钙、三氯化铬的混合物;
所述维生素为维生素B3、维生素C、维生素E、叶酸、烟酰胺、泛酸混合物;
所述豆类提取物为黑豆提取物。
实施例3
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分90份、增塑剂6份、增稠剂4份、甜味剂2份、纯净水130份、微量元素9份、维生素4份。
所述主成分的原料组份及重量份配比为:金银花2份、甘草6份、红枣16份、虫草提取物16份、豆类提取物26份、三七2份、菊花6份、灵芝孢子粉2份、人参2份、黑枸杞11份、芝麻粉10份、核桃粉6份、酪蛋白0.2份、α-乳白蛋白3份、雪蛤4份、鱼油6份。
所述增稠剂是琼脂;
所述增塑剂是丙二醇;
所述甜味剂为低聚果糖;
所述微量元素为亚硒酸钠、磷酸三钙、乳酸锌的混合物;
所述维生素为维生素A、维生素B1、维生素B2、维生素B3、维生素B12、维生素C、维生素E、叶酸、维生素D、烟酰胺、泛酸的混合物;
所述豆类提取物为青豆提取物。
实施例4
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分100份、增塑剂10份、增稠剂7份、甜味剂3份、纯净水150份、微量元素9份、维生素5份。
所述主成分的原料组份及重量份配比为:金银花3份、甘草7份、红枣18份、虫草提取物20份、豆类提取物30份、三七3份、菊花8份、灵芝孢子粉4份、人参2份、黑枸杞13份、芝麻粉14份、核桃粉8份、酪蛋白0.4份、α-乳白蛋白4份、雪蛤6份、鱼油8份。
所述增稠剂是结冷胶;
所述增塑剂是聚乙二醇;
所述甜味剂为三氯蔗糖;
所述微量元素为磷酸三钙;
所述维生素为维生素B3、维生素B12、维生素C、维生素E、叶酸、泛酸中的混合物;
所述豆类提取物为黄豆提取物和青豆提取物的混合物。
实施例5
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分140份、增塑剂12份、增稠剂5份、甜味剂3份、纯净水160份、微量元素11份、维生素4份。
所述主成分的原料组份及重量份配比为:金银花1份、甘草8份、红枣17份、虫草提取物21份、豆类提取物32份、三七2份、菊花7份、灵芝孢子粉2份、人参3份、黑枸杞12份、芝麻粉11份、核桃粉9份、酪蛋白0.4份、α-乳白蛋白3份、雪蛤6份、鱼油9份。
所述增稠剂是普鲁兰多糖;
所述增塑剂是山梨醇和聚乙二醇的混合物;
所述甜味剂为三氯蔗糖;
所述微量元素为亚硒酸钠、磷酸三钙、乳酸锌的混合物;
所述维生素为维生素A、维生素B1、叶酸、维生素D的混合物;
所述豆类提取物为青豆提取物合黑豆提取物的混合物。
实施例6
一种虫草钙压片组合物,所述组合物的原料组份及重量份配比为:
主成分135份、增塑剂9份、增稠剂6份、甜味剂3份、纯净水185份、微量元素14份、维生素4份。
所述主成分的原料组份及重量份配比为:金银花2份、甘草6份、红枣19份、虫草提取物28份、豆类提取物38份、三七3份、菊花9份、灵芝孢子粉5份、人参3份、黑枸杞14份、芝麻粉14份、核桃粉9份、酪蛋白0.5份、α-乳白蛋白4份、雪蛤7份、鱼油10份。
所述增稠剂是瓜尔豆胶;
所述增塑剂是山梨醇;
所述甜味剂为低聚木糖;
所述微量元素为磷酸三钙;
所述维生素为维生素B1、维生素C、维生素E、叶酸的混合物;
所述豆类提取物为黄豆提取物、青豆提取物、黑豆提取物的混合物。
实施例7
所述虫草钙压片组合物的制备方法,包括如下步骤:
步骤一、原料准备;
步骤二、称量、配料;
步骤三、植物提取物的制备;
步骤四、干燥;
步骤五、混合;
步骤六、灭菌、包装。
所述步骤一、原料准备;
其中,所述原料准备包括:
(一)原料预处理
步骤(1)将金银花、甘草、红枣、菊花、人参、黑枸杞、芝麻粉等原料进行清洗,去除杂质。
步骤(2)将步骤(1)中经过清洗的原料,放在-10的冰箱中恒温3h,然后取出放在真空冷冻干燥机内,先以3℃/min的降温速度冷冻至-30℃,保持4h,然后将冷冻原料放在室温、通风的条件下解冻摊晾至原料表面的冰晶融化、水分挥发,解冻摊晾过程中每隔10分钟翻动一次冷冻原料,解冻摊晾11h,即得到解冻原料;
步骤(3)初烘,将步骤(2)中得到的解冻原料均匀的添加至烘干机中,温度为55℃的条件下初烘至含水量为10%的程度,初烘20min,即得到初烘原料,再将初烘原料摊晾2h,即得到待复烘原料;
步骤(4)复烘,将步骤(3)中得到的待复烘原料均匀的添加至烘干机中,温度为60℃的条件下复烘至待复烘原料含水量为5%,复烘20min,即得到成品待用原料,所述烘干机的型号为7CHB-5,产量≥30kg/h。
(二)其它组份原料的预处理
灵芝孢子粉的加工工艺为:取灵芝菌盖在9厘米以上,菌柄2厘米以内,干燥、无霉变的灵芝超微粉碎加工。所述超微粉碎加工工艺为,将灵芝密封置于-10℃的冰箱中恒温1h,然后取出,置于真空冷冻干燥机内,先以10℃/min的降温速度冷冻-50℃,保持4h,然后再放置在库温为-36℃的冷冻库中恒温冷冻3h,在超微破壁粉碎机粉碎至200目以上。
所述步骤二、称量、配料;
将步骤一中得到的预处理后的原料,按照相应的配比进行称量;
步骤三、植物提取物的制备;
所述步骤三的植物提取物的制备,具体包括:
(一)虫草提取物的制备
步骤(1)将虫草在蓝光灭菌机里进行灭菌,灭菌时间2min,然后进行干燥,干燥温度60℃,干燥时间8h,干燥时附加远红外照射,远红外辐射强度0.4W/cm2;干燥后储藏在冷柜中,储藏温度为-10℃;
步骤(2)将冷冻的虫草粉碎至200目,得到虫草粉;
步骤(3)将虫草粉进行造粒,造粒后的颗粒平均粒径为1.0mm;
步骤(4)将步骤(3)重的虫草颗粒,置于萃取釜中;
步骤(5)将经过预热的去离子水以小于或等于50ml/min的流速注入到萃取釜中;
步骤(6)萃取;
步骤(7)离心:将萃取液在2000r/min条件下,离心处理20min,取上清液;
步骤(8)过滤:离心后得到的上清液过微滤陶瓷薄膜,得到滤液,沉淀后取上清精油,得到虫草精油粗品;
步骤(9)虫草精油粗品倒入分子蒸馏仪的物料瓶中并关闭分子蒸馏系统与外界联通的所有阀门,打开冷凝水,将液氮加入到冷阱中,启动真空泵进行脱气,至液面无气泡逸出;
步骤(10)设定分子蒸馏蒸发面温度为为50℃、真空度为200Pa,待温度与真空度达到设定值时打开进料阀,调节进料流速为3mL、转速为400r/min脱气后进行粗制精油的分子蒸馏,收集重组分纯化浓缩精油的馏余物,得到虫草提取物,经检测,其中虫草酸含量大于10%,不饱和脂肪酸含量大于90%。
通过本申请所述提取物植物制备方法所取得的虫草提取物,有效成分含量高,损失小,最大程度的保留了其有效成分。
所述微滤陶瓷薄膜过滤中,所述陶瓷薄膜为本申请针对所述虫草植物特性,为最大限度提高提取虫草有效成分的提取率,保证其有效成分的活性而专门设计的。申请人经过大量的研究发现,在现有技术中,研究人员往往忽略对制备提取物过滤步骤的忽略,从而导致提取的效率不高,有效成分的活性低,营养成分损失。通过大量的研究,针对现有技术中的不足,本申请中采用氧化锆基陶瓷薄膜,截留分子量为1500MW,微滤温度为25℃;所述薄膜的厚度为15微米;所述薄膜的原料组份及重量配比为:氮化硅10份、氧化钇稳定的氧化锆8份、碳化钛3份、碳纤维8份、氧化锌5份、氮化铝8份、立方氮化硼4份;
通过本步骤所使用的陶瓷薄膜过滤,对提取物产品无污染,能有效过滤杂质,为提高提取物的纯度,打下了坚实的基础。
在步骤(6)的萃取步骤中,使用超声强化亚临界水进行萃取,包括控制系统部分、操作系统部分和超声强化部分,控制系统部分与操作系统部分之间采用电信号的方式连接。所述亚临界水萃取法,在5Mpa、150℃条件下,对反应釜中的物质进行90min的萃取,然后分离反应釜中的物质。
(二)豆类提取物的制备
步骤a、将豆类洗净,晾干,破碎至0.1cm,豆类料与水的重量比为1:2放入蒸煮罐中进行高温高压提取,得到豆汁和豆渣混合物;将混合物过滤,所述过滤分为粗滤和微滤,所述粗滤使用纱布,所述微滤使用微滤陶瓷薄膜A;所述微滤陶瓷薄膜A为氧化铝基陶瓷薄膜,截留分子量为2000MW,微滤温度为25℃;所述微滤陶瓷薄膜A的厚度为20微米;所述微滤陶瓷薄膜A的原料组份及重量配比为:氧化铝5份、氧化镁1份、氧化钇稳定的氧化锆6份、Sc2O31份、碳纤维5份、氧化钙1份、BeO 5份、氮化硅1份、碳化硅5份。
然后将粗滤与微滤取得的滤渣进行混合,对滤渣混合物进行蒸煮提取:滤渣在蒸煮罐中的提取温度为125℃,提取时间为120min;将提取后的滤渣汁经过100目的过滤网过滤后,取得的液体与粗滤和微滤取得的滤液进行混合,再进行下一步滤液提纯处理。
步骤b、将步骤一中得到的滤液进行提纯处理,依次包括如下步骤,管式离心分离、超滤膜过滤、脱色脱味、纳滤膜浓缩、离心喷雾干燥;
其中,管式离心分离:将经过过滤后的滤液进行高速离心分离,离心机转速为12000r/min,离心后的脱脂滤液进入超滤膜过滤工序;
其中,超滤膜过滤:将得到的脱脂滤液用截留分子量为1000道尔顿的超滤膜过滤去除清液中的大分子物质,所述超滤膜的膜压为1MPa,超滤温度为25℃;然后进入脱色脱味工序;
其中,脱色脱味:向经过超滤膜过滤后得到的清液中加入活性碳进行脱色脱味,活性碳的加入量为超滤膜过滤后滤液重量的5%,将加入活性碳后的清液升温至85℃,并保温10min,然后降温至60℃,静置30min后经过孔径为0.2-0.5μm的多层膜过滤器进行脱碳处理;然后进入纳滤膜浓缩工序
其中,纳滤膜浓缩:将脱碳处理的清液用孔径分为300道尔顿的纳滤膜去除大部分水分和无机盐,将清液浓缩至固形物含量为40%,所述纳滤膜的膜压为0.5MPa,纳滤温度为40℃;然后进入离心喷雾干燥工序;
其中,离心喷雾干燥:将经过浓缩的滤液液经离心喷雾干燥塔干燥,干燥过程中的进口温度为190℃,出口温度为85℃,即得到豆类提取物。
步骤四、干燥;
所述干燥为热风-红外干燥,热风温度55℃,远红外辐射强度1W/cm2。
步骤五、混合;
将步骤三中制备的植物提取物,与步骤二中准备好的配料,按照原料配比组分进行搅拌,混合;
(1)制粒:将各种原料混合好后放入制粒机,筛底选20目筛;
(2)干燥:制粒结束后,迅速干燥,避免结块,干燥温度50℃,干燥后的组合物水分为8%;
(3)整粒:将干燥好的组合物颗粒过10目筛,使颗粒粒度分布均匀,流动性更好;
步骤六、灭菌、包装。
高温100±2℃灭菌14±2分钟,检验合格后,复合袋分装后包装。
1、测试:
(1)总钙量测定
取实施例1中最终组合物产品0.3g,置瓷坩埚内,加硫酸0.5-1.0ml湿润,低温加热至硫酸蒸气除尽,在700-800℃炽灼至灰化,放冷,加稀盐酸10ml,加热搅拌溶解,完全转移至锥形瓶中,加水10ml,加甲基红指示液1滴,加氨试液使溶液由红色变成微黄色,加新配制的20%三乙醇胺溶液10ml,得反应液I;另取水10ml,加氨-PH=10.0氯化铵缓冲液10ml、稀硫酸镁试剂2滴与铬黑T指示剂少许,滴加0.05mol/L乙二胺四醋酸二钠液至溶液显纯蓝色,加入所述反应液I,摇匀,用0.05mol/L乙二胺四醋酸二钠液滴定至溶液自紫红色变成纯蓝色,记录滴定所用0.05mol/L乙二胺四醋酸二钠液的体积;根据每1ml0.05mol/L乙二胺四醋酸二钠相当于2.004mg钙,以及滴定所用0.05mol/L乙二胺四醋酸二钠液的体积,计算即得。
每粒所述胶囊剂含总钙量不得少于55.0mg。
(2)、提高免疫力功能性测试:
试验产品:
试验1组:常规组合物:维生素A、维生素B1、维生素B2、维生素B6、维生素C、维生素E和叶酸共0.7g(各0.1g),钙、铁、锌和硒共2g(各0.5g)。
试验2组:实施例1组合物3.2g。
试验3组:实施例2组合物:1.109g。
试验4组:实施例3组合物:5.9g。
试验5组:实施例4组合物:0.5g。
试验6组:实施例5合物:1.909g
试验动物:昆明种雌性小白鼠,体重18-22g。
试验方法1:取小鼠随机分组:空白对照组、试验组合物,小鼠每天灌喂组合物1次,每次给量为0.15g/kg,空白对照组给予等容量的蒸馏水。连续30d后分别对小鼠进行各项免疫指标测定。
小鼠迟发型变态反应(DTH)测定:于灌喂第26天,给小鼠腹腔注射2%绵羊红细胞(SRBC)0.2ml/只进行致敏,于免疫后第4天每鼠左后足环部皮下注射20%SRBC(20μl/只)进行攻击。并于攻击前和攻击后24h测量每鼠左后足肠同一部位厚度,计算攻击前、后的差值,进行方差分析。试验结果见表2。
表2对小鼠DTH测定结果(24h)
注:与对照组比较**P<0.01,*P<0.05;与试验1组比较△P<0.05;与试验2组比较#P<0.05。
试验方法2:取小鼠随机分组:空白对照组、试验组合物,小鼠每天灌喂组合物1次,每次给量为0.15g/kg,空白对照组给予等容量的蒸馏水。连续30d后分别对动物进行各项免疫指标测定。
ConA诱导小鼠脾淋巴细胞转化实验(MTT法):对各组小鼠无菌取脾,制脾细胞悬液,用RPMI 1640完全培养液调整脾细胞浓度为3x109个/L,按照程序中MTr法进行淋巴细胞增殖反应,最后在752-C紫外可见分光光度计570nm波长处测其吸光度值(A),计算ConA+与ConA-各孔的吸光度值差。进行方差分析。试验结果见表3。
表3对小鼠脾淋巴细胞转化试验结果测定结果(24h)
注:与对照组比较*P<0.05;与试验1组比较△P<0.05;与试验3组比较#P<0.05。
试验方法3:取小鼠随机分组:空白对照组、试验组合物,小鼠每天灌喂组合物1次,每次给量为0.2g/kg,空白对照组给予等容量的蒸馏水。连续30d后分别对动物进行各项免疫指标测定。
血清溶血素测定:于灌喂第25天给小鼠腹腔注射2%SRBC(0.2ml/只),于免疫后第5天摘眼球采血,分离血清并在微量血凝板上进行血清溶血素测定:37℃孵育3h,统计血球凝集度,计算相应抗体积数。进行方差分析,试验结果见表4。
表4对小鼠血清溶血素测定结果
注:与对照组比较**P<0.01,*P<0.05;与试验1组比较△P<0.05;与试验4组比较#P<0.05。
试验方法5:取小鼠随机分组:空白对照组、试验组合物,小鼠每天灌喂组合物1次,每次给量为0.2g/kg,空白对照组给予等容量的蒸馏水。连续30d后分别对动物进行各项免疫指标测定。
抗体生成细胞(PFc)检测:于灌喂第25天给小鼠腹腔注射2%SRBC0.2ml/只,于免疫后第5天处死,解剖取脾制备脾细胞悬液,用RPMI 1640完全培养液调整脾细胞浓度为5x109个/L。按程序方法制备琼脂糖玻片,在CO2培养箱(37℃、5%CO2)中温育1.5h后加补体,再温育1.5h,计数每张琼脂薄层玻片上形成的溶血空斑数。进行方差分析,试验结果见表5。
表5对小鼠抗体生成细胞检测结果
注:与对照组比较**P<0.01,*P<0.05;与试验1组比较△P<0.05;与试验2组比较#P<0.05。
试验结论:上述试验表明,本发明物组合物具有很好提高免疫力的作用。
最后应说明的是:显然,上述实施例仅仅是为清楚地说明本申请所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本申请型的保护范围之中。
Claims (8)
1.一种虫草钙压片组合物,其特征在于,所述组合物的原料组份及重量份配比为:
主成分80-150份、增塑剂5-15份、增稠剂3-8份、甜味剂1-5份、纯净水120-200份、微量元素8-15份、维生素3-5份。
2.根据权利要求1所述的虫草钙压片组合物,其特征在于,所述主成分的原料组份及重量份配比为:金银花1-3份、甘草5-8份、红枣15-20份、虫草提取物15-30份、豆类提取物25-40份、三七1-3份、菊花5-9份、灵芝孢子粉1-5份、人参1-3份、黑枸杞10-15份、芝麻粉9-15份、核桃粉5-10份、酪蛋白0.1-0.5份、α-乳白蛋白2-4份、雪蛤3-7份、鱼油5-10份。
3.根据权利要求1所述的虫草钙压片组合物,其特征在于,所述增稠剂选自淀粉、纤维素、海藻酸钠、卡拉胶、琼脂、结冷胶、普鲁兰多糖、刺槐豆胶、瓜尔豆胶、黄原胶中的一种、两种或两种以上任意比例的混合物;
所述增塑剂是甘油、丙二醇、山梨醇、聚乙二醇中的一种、两种或两种以上任意比例的混合物;
所述甜味剂为木糖醇、三氯蔗糖、低聚木糖或低聚果糖中的一种;
所述微量元素为亚硒酸钠、乳酸镁、乳酸锌、三氯化铬或磷酸三钙中的一种、两种或两种以上的混合物;
所述维生素为维生素A、维生素B1、维生素B2、维生素B3、维生素B12、维生素C、维生素E、叶酸、维生素D、烟酰胺、泛酸中的一种或几种混合物;
所述豆类提取物为黄豆提取物或青豆提取物或黑豆提取物中的一种或几种提取物的混合物。
4.根据权利要求1所述的虫草钙压片组合物,其特征在于,所述组合物的原料组份及重量份配比为:
主成分80份、增塑剂5份、增稠剂3份、甜味剂1份、纯净水120份、微量元素8份、维生素3份。
5.根据权利要求1所述的虫草钙压片组合物,其特征在于,所述组合物的原料组份及重量份配比为:
主成分150份、增塑剂15份、增稠剂8份、甜味剂5份、纯净水200份、微量元素15份、维生素5份。
6.根据权利要求2所述的虫草钙压片组合物,其特征在于,所述主成分的原料组份及重量份配比为:金银花1份、甘草5份、红枣15份、虫草提取物15份、豆类提取物25份、三七1份、菊花5份、灵芝孢子粉1份、人参1份、黑枸杞10份、芝麻粉9份、核桃粉5份、酪蛋白0.1份、α-乳白蛋白2份、雪蛤3份、鱼油5份。
7.根据权利要求2所述的虫草钙压片组合物,其特征在于,所述主成分的原料组份及重量份配比为:金银花3份、甘草8份、红枣20份、虫草提取物30份、豆类提取物40份、三七3份、菊花9份、灵芝孢子粉5份、人参3份、黑枸杞15份、芝麻粉15份、核桃粉10份、酪蛋白0.5份、α-乳白蛋白4份、雪蛤7份、鱼油10份。
8.一种权利要求1-7任意一项所述虫草钙压片组合物的制备方法,其特征在于,包括如下步骤:
步骤一、原料准备;
步骤二、称量、配料;
步骤三、植物提取物的制备;
步骤四、干燥;
步骤五、混合;
步骤六、灭菌、包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910113725.4A CN109645476A (zh) | 2019-02-14 | 2019-02-14 | 一种虫草钙压片组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910113725.4A CN109645476A (zh) | 2019-02-14 | 2019-02-14 | 一种虫草钙压片组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109645476A true CN109645476A (zh) | 2019-04-19 |
Family
ID=66121303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910113725.4A Pending CN109645476A (zh) | 2019-02-14 | 2019-02-14 | 一种虫草钙压片组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109645476A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110585260A (zh) * | 2019-10-31 | 2019-12-20 | 北京本草方源药业集团有限公司 | 一种单味冻干粉剂及其制备方法 |
CN110639005A (zh) * | 2019-10-29 | 2020-01-03 | 北京本草方源药业集团有限公司 | 一种复方冻干粉剂及其制备方法 |
CN110664764A (zh) * | 2019-11-06 | 2020-01-10 | 北京本草方源药业集团有限公司 | 一种单味低温真空干燥提取粉及其提取方法 |
CN110755389A (zh) * | 2019-11-05 | 2020-02-07 | 北京本草方源药业集团有限公司 | 一种复方低温真空干燥提取粉及其提取方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101711858A (zh) * | 2009-10-22 | 2010-05-26 | 岳德玺 | 一种治疗癌症的药 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN101822765A (zh) * | 2010-01-28 | 2010-09-08 | 江西新赣江药业有限公司 | 一种益肾壮骨、补血益精中药复方制剂的质量检测方法 |
CN102133241A (zh) * | 2011-03-15 | 2011-07-27 | 郭景龙 | 一种具有提高免疫力作用的药物组合物 |
CN102559386A (zh) * | 2011-12-30 | 2012-07-11 | 浙江省农业科学院 | 一种柑橘类精油精制浓缩的制备方法 |
CN104705475A (zh) * | 2015-04-08 | 2015-06-17 | 王书敏 | 一种虫草钙压片糖果及其制备方法 |
CN108947738A (zh) * | 2018-04-04 | 2018-12-07 | 刁杰明 | 一种含有碳酶柠檬酸的生物肥及其制备方法 |
CN109287841A (zh) * | 2018-09-04 | 2019-02-01 | 王书敏 | 一种通过生物技术加工牦牛骨的方法 |
-
2019
- 2019-02-14 CN CN201910113725.4A patent/CN109645476A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101711858A (zh) * | 2009-10-22 | 2010-05-26 | 岳德玺 | 一种治疗癌症的药 |
CN101822765A (zh) * | 2010-01-28 | 2010-09-08 | 江西新赣江药业有限公司 | 一种益肾壮骨、补血益精中药复方制剂的质量检测方法 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN102133241A (zh) * | 2011-03-15 | 2011-07-27 | 郭景龙 | 一种具有提高免疫力作用的药物组合物 |
CN102559386A (zh) * | 2011-12-30 | 2012-07-11 | 浙江省农业科学院 | 一种柑橘类精油精制浓缩的制备方法 |
CN104705475A (zh) * | 2015-04-08 | 2015-06-17 | 王书敏 | 一种虫草钙压片糖果及其制备方法 |
CN108947738A (zh) * | 2018-04-04 | 2018-12-07 | 刁杰明 | 一种含有碳酶柠檬酸的生物肥及其制备方法 |
CN109287841A (zh) * | 2018-09-04 | 2019-02-01 | 王书敏 | 一种通过生物技术加工牦牛骨的方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110639005A (zh) * | 2019-10-29 | 2020-01-03 | 北京本草方源药业集团有限公司 | 一种复方冻干粉剂及其制备方法 |
CN110585260A (zh) * | 2019-10-31 | 2019-12-20 | 北京本草方源药业集团有限公司 | 一种单味冻干粉剂及其制备方法 |
CN110755389A (zh) * | 2019-11-05 | 2020-02-07 | 北京本草方源药业集团有限公司 | 一种复方低温真空干燥提取粉及其提取方法 |
CN110664764A (zh) * | 2019-11-06 | 2020-01-10 | 北京本草方源药业集团有限公司 | 一种单味低温真空干燥提取粉及其提取方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101999575B (zh) | 一种增强机体免疫力并能控制糖尿病的产品 | |
CN109645476A (zh) | 一种虫草钙压片组合物及其制备方法 | |
CN102511869B (zh) | 红枣生姜浓浆 | |
CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
CN104017700B (zh) | 一种调和养生酒及其制备方法 | |
CN101711858B (zh) | 一种治疗癌症的药 | |
CN108703249A (zh) | 一种胶原蛋白产品及其制备方法 | |
CN111802476A (zh) | 一种提高儿童睡眠质量的奶粉及其制备方法 | |
CN106418545A (zh) | 一种营养均衡的功能性食品 | |
CN107094974A (zh) | 一种黑枸杞保健糖果及其制备方法 | |
CN103230064A (zh) | 山楂复合饮料 | |
CN110800999A (zh) | 一种多功能营养全粉及其生产方法 | |
CN101253986B (zh) | 多功能营养复合保健饮料及其制备方法 | |
KR101642176B1 (ko) | 성장촉진 조성물 | |
CN103141849A (zh) | 一种可延缓衰老的膳食养生粉制备工艺 | |
CN116602408B (zh) | 一种含有明日叶多肽的微生态提取物及其制备方法和应用 | |
CN102511875A (zh) | 一种适合术后人群饮用的红枣浓浆 | |
CN102511876A (zh) | 山楂红枣浓浆 | |
CN110731503A (zh) | 一种参杞蛹虫草片及其制备方法 | |
CN1326541C (zh) | 枸杞蜂王浆胶囊及其制备方法 | |
CN113749152A (zh) | 一种健康养生强身饮品及其制备方法 | |
CN104770787B (zh) | 一种西洋红参沙棘饮料的制备方法 | |
CN102511868A (zh) | 一种添加维生素的红枣阿胶浓浆 | |
CN106418498A (zh) | 以柠檬、高良姜为主要原料制备酵素的方法 | |
CN104255922A (zh) | 适宜三高人群饮用的保健牛奶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |